| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
5,7,3',4'-Tetramethoxyflavone targets multiple pathways. It selectively inhibits multidrug resistance. It exerts chondroprotective activity by targeting β-catenin signaling. It has antifungal, antimalarial, antimycobacterial, and anti-inflammatory activities. Its mechanism of action likely involves modulation of various signaling pathways, including those involved in inflammation, cell proliferation, and drug resistance.
|
|---|---|
| ln Vitro |
In vitro, 5,7,3',4'-Tetramethoxyflavone has antifungal, antimalarial, antimycobacterial, and anti-inflammatory activities. It selectively inhibits multidrug resistance. It exerts chondroprotective activity by targeting β-catenin signaling. Quantitative IC50 values for its activities are not detailed in the publicly available sources. These diverse in vitro activities make it a compound of interest for studying various disease models.
|
| ln Vivo |
In vivo activity data for 5,7,3',4'-Tetramethoxyflavone is limited in publicly available literature. As a compound with diverse biological activities in vitro, it is hypothesized to exhibit similar effects in vivo. Its chondroprotective activity suggests potential for in vivo studies in osteoarthritis models. Its anti-inflammatory and antimicrobial activities also suggest potential for in vivo efficacy studies. However, specific in vivo data, including pharmacokinetic and pharmacodynamic parameters, have not been detailed.
|
| Enzyme Assay |
For cell-free assays, the chondroprotective activity of 5,7,3',4'-Tetramethoxyflavone can be studied by measuring its effect on β-catenin signaling using reporter gene assays or by measuring the expression of β-catenin target genes. Its anti-inflammatory activity can be assessed by measuring its inhibition of inflammatory enzymes, such as COX-2 or LOX. Its antimicrobial activity can be assessed using standard broth microdilution methods to determine MIC values.
|
| Cell Assay |
For in vitro cellular assays, the chondroprotective activity of 5,7,3',4'-Tetramethoxyflavone can be assessed in chondrocyte cell lines. Cells are treated with the compound, and the expression of chondrogenic markers (e.g., collagen type II, aggrecan) and the inhibition of catabolic factors (e.g., MMP-13) are measured. Its anti-inflammatory activity is assessed in LPS-stimulated macrophages by measuring cytokine production. Its anticancer activity is assessed in cancer cell lines by measuring cell viability.
|
| Animal Protocol |
For in vivo studies, 5,7,3',4'-Tetramethoxyflavone could be administered orally in animal models of osteoarthritis, inflammation, or cancer. In osteoarthritis models, endpoints include cartilage degradation, pain, and joint inflammation. In inflammation models, endpoints include inflammatory cytokine levels and tissue histopathology. In cancer models, endpoints include tumor growth inhibition.
|
| ADME/Pharmacokinetics |
5,7,3',4'-Tetramethoxyflavone (CAS 855-97-0) has a molecular formula of C19H18O6 and a molecular weight of 342.34 g/mol. Its IUPAC name is 2-(3,4-dimethoxyphenyl)-5,7-dimethoxy-4H-chromen-4-one. Purity is ≥98%. Appearance: A solid. Solubility: DMSO: Soluble; Methanol: Soluble. Storage: -20°C.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural polymethoxyflavone from edible plants, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies to confirm that observed effects are not due to a general reduction in cell viability.
|
| References | |
| Additional Infomation |
3',4',5,7-Tetramethoxyflavonoids have been reported to be found in Boesenbergia rotunda, Citrus reticulata, and other organisms with available data.
5,7,3',4'-Tetramethoxyflavone is a research-grade compound and is not approved for therapeutic use. It serves primarily as a pharmacological tool for studying multidrug resistance, inflammation, and chondroprotection. Its mechanism of action involves modulation of β-catenin signaling and inhibition of inflammatory pathways. It is a natural product from Murraya exotica and Kaempferia parviflora. No clinical trials have been reported. |
| Molecular Formula |
C19H18O6
|
|---|---|
| Molecular Weight |
342.3426
|
| Exact Mass |
342.11
|
| CAS # |
855-97-0
|
| PubChem CID |
631170
|
| Appearance |
White to off-white solid powder
|
| Density |
1.243g/cm3
|
| Boiling Point |
528.8ºC at 760 mmHg
|
| Melting Point |
195-197°C
|
| Flash Point |
233.9ºC
|
| Index of Refraction |
1.574
|
| LogP |
3.494
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
504
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
CLXVBVLQKLQNRQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H18O6/c1-21-12-8-17(24-4)19-13(20)10-15(25-18(19)9-12)11-5-6-14(22-2)16(7-11)23-3/h5-10H,1-4H3
|
| Chemical Name |
2-(3,4-dimethoxyphenyl)-5,7-dimethoxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~8.33 mg/mL (~24.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9211 mL | 14.6054 mL | 29.2107 mL | |
| 5 mM | 0.5842 mL | 2.9211 mL | 5.8421 mL | |
| 10 mM | 0.2921 mL | 1.4605 mL | 2.9211 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
